The Filing Desk

Iovance Biotherapeutics

IOVA · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

IOVA · Last close · November 13, 2026
$7.76
Value Iovance Biotherapeutics yourself

Iovance Biotherapeutics' revenue rose 60.6% to $264 million in fiscal 2025. Its operating margin was −153.1%, up from −240.9% a year earlier. Free cash flow was −$336 million. The diluted share count rose 23.3%.

IOVANCE BIOTHERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001104659-26-018899 Updated
Revenue
$264M
60.6%
Operating margin
−153.1%
87.8 pts
Net income
−$391M
 
Free cash flow
−$336M
 
Return on equity
−55.5%
2.0 pts
Market cap
$3M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Return on capital for fiscal 2025 is blank: invested capital is small next to total assets (cash nearly matches equity and debt), so the ratio isn't meaningful. Piotroski F-score for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Iovance Biotherapeutics does

Iovance is a commercial-stage biopharmaceutical company, meaning it has approved products on sale. It makes cell therapies for solid-tumor cancers called tumor infiltrating lymphocyte (TIL) therapies. Each one is made from a patient's own immune cells, which are grown into very large numbers in a centralized manufacturing process and given back to the patient.

It has two commercial products. Amtagvi (lifileucel) is a one-time, individualized T cell therapy for adults with advanced melanoma, a skin cancer, who have already been treated. It is given with a short course of chemotherapy-type conditioning and Proleukin (aldesleukin), an interleukin-2 drug that Iovance also sells and that is used in other applications as well.

Amtagvi is approved in the United States and Canada. Approvals are pending in the United Kingdom, Australia and Switzerland. In the European Union, Iovance withdrew its first marketing application in July 2025. The company has restructured, including cutting its workforce.

Its biggest risks, as it describes them

  • It has a history of operating losses and may never be profitable, even with Amtagvi approved.
  • Its therapies are novel approaches, so the path to approval and acceptance is uncertain.
  • Its newer manufacturing process may not meet FDA rules or lower the cost of making the therapy.
  • It may not gain the expected benefits from its restructuring and workforce reductions.
  • It faces competition from other drug companies and from non-profit institutions.
From Iovance Biotherapeutics's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Iovance Biotherapeutics lost money in fiscal 2025: a net loss of $391 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments504472280324297
Debt incl. finance leases1111—
Net debt (negative means net cash)−503−471−279−323—
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x—
Interest coverage—————
Current ratio5.7x5.2x2.8x3.7x3.2x
Quick ratio5.7x5.2x2.7x3.3x2.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Iovance Biotherapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Iovance Biotherapeutics says to expect

  • Full year 2026: total product revenueIovance remains on track towards achieving its guidance range of $410 to $420 million in total product revenue in 2026.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Iovance Biotherapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score—6 of 9—
Rule of 40—13,477.1%−67.0%
Altman Z''−7.58−5.32−7.27
Accruals ratio−11.4%−2.3%−9.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPass—
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose—PassFail
Revenue rose relative to assets—PassPass
F-score—6 of 9—
Companies that report no gross profit are scored on the other eight.

Compare

Put Iovance Biotherapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Iovance BiotherapeuticsFY2560.6%−153.1%−127.6%———
ArvinasFY25−0.3%−45.1%−105.0%——5Compare
Ligand PharmaceuticalsFY2560.4%15.3%18.2%4.9%−3.8x5Compare
VericelFY2516.4%4.0%9.0%———Compare
Adaptive BiotechnologiesFY2554.8%−20.6%−17.7%−37.2%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue000————1164264
Revenue growth————————13,699.0%60.6%
Gross profit———————07190
Research and development2772100166202259295333276300
Operating income−54−93−128−207−262−343−399−461−395−403
Net income−53−92−124−198−260−342−396−444−372−391
Diluted EPS (US$)−1.85−1.41−1.27−1.59−1.88−2.23−2.49−1.89−1.28−1.09
Diluted shares (millions)0000000000
Cash flow
Cash from operations−33−79−101−159−205−228−293−362−353−302
Capital expenditure2117473820221134
Free cash flow−34−80−102−166−252−266−313−384−364−336
Dividends paid0000000000
Share buybacks0000000000
Acquisitions000000021300
Stock-based compensation191220244170846311062
Balance sheet at fiscal year end
Cash and short-term investments166145386307635504472280324297
Debt incl. finance leases—————1111—
Total assets172155481345768777664780910913
Total liabilities5101546112156164196200215
Shareholders' equity167146466299656622500585710699
Margins and ratios
Gross margin———————13.1%43.2%34.3%
Operating margin———————−38,735.0%−240.9%−153.1%
Net margin———————−37,345.4%−226.8%−148.4%
Free cash flow margin———————−32,305.3%−221.9%−127.6%
Rule of 40 (growth + FCF margin)————————13,477.1%−67.0%
Return on capital——————−428.6%−217.5%−90.1%—
Return on equity−39.0%−58.9%−40.4%−51.6%−54.3%−53.5%−70.6%−81.9%−57.5%−55.5%
Return on assets−38.1%−56.3%−38.9%−47.9%−46.6%−44.3%−54.9%−61.5%−44.0%−42.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Iovance Biotherapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Iovance Biotherapeutics.